HK1068349A1 - Substituted benzopyrans as selective estrogen receptor-beta agonists - Google Patents

Substituted benzopyrans as selective estrogen receptor-beta agonists

Info

Publication number
HK1068349A1
HK1068349A1 HK05100628A HK05100628A HK1068349A1 HK 1068349 A1 HK1068349 A1 HK 1068349A1 HK 05100628 A HK05100628 A HK 05100628A HK 05100628 A HK05100628 A HK 05100628A HK 1068349 A1 HK1068349 A1 HK 1068349A1
Authority
HK
Hong Kong
Prior art keywords
estrogen receptor
selective estrogen
beta agonists
agonists
substituted benzopyrans
Prior art date
Application number
HK05100628A
Other languages
English (en)
Inventor
Jeffrey Alan Dodge
Venkatesh Gary Krishnan
Charles Willis Lugar Iii
Blake Lee Neubauer
Bryan Hurst Norman
Lance Allen Pfeifer
Timothy Ivo Richardson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of HK1068349A1 publication Critical patent/HK1068349A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Obesity (AREA)
  • Pyrane Compounds (AREA)
HK05100628A 2001-11-19 2005-01-24 Substituted benzopyrans as selective estrogen receptor-beta agonists HK1068349A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33276601P 2001-11-19 2001-11-19
US36362202P 2002-03-11 2002-03-11
PCT/US2002/033622 WO2003044006A1 (fr) 2001-11-19 2002-11-07 Benzopyrans substitues convenant comme agonistes du recepteur aux oestrogenes beta

Publications (1)

Publication Number Publication Date
HK1068349A1 true HK1068349A1 (en) 2005-04-29

Family

ID=26988373

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05100628A HK1068349A1 (en) 2001-11-19 2005-01-24 Substituted benzopyrans as selective estrogen receptor-beta agonists

Country Status (24)

Country Link
US (1) US7217734B2 (fr)
EP (1) EP1448544B1 (fr)
JP (1) JP4381810B2 (fr)
KR (1) KR100950616B1 (fr)
CN (1) CN1312147C (fr)
AT (1) ATE362471T1 (fr)
AU (1) AU2002359283B2 (fr)
CA (1) CA2467013C (fr)
CY (1) CY1106726T1 (fr)
DE (1) DE60220179T2 (fr)
DK (1) DK1448544T3 (fr)
EA (1) EA007382B1 (fr)
EC (1) ECSP045113A (fr)
ES (1) ES2286322T3 (fr)
HK (1) HK1068349A1 (fr)
HR (1) HRP20040439A2 (fr)
HU (1) HU229351B1 (fr)
IL (3) IL161325A0 (fr)
MX (1) MXPA04004703A (fr)
NO (1) NO328563B1 (fr)
NZ (1) NZ531850A (fr)
PL (1) PL205733B1 (fr)
PT (1) PT1448544E (fr)
WO (1) WO2003044006A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE406373T1 (de) 2003-04-21 2008-09-15 Lilly Co Eli Substituierte benzopyrane als selektive antagonisten am östrogenrezeptor-beta
ATE457308T1 (de) * 2003-04-21 2010-02-15 Lilly Co Eli Substituierte benzopyrane als selektive antagonisten am östrogenrezeptor-beta
EP1789420A2 (fr) 2004-09-07 2007-05-30 Wyeth, A Corporation of the State of Delaware 6h-[1]benzopyrano[4,3-b]quinolines et leur utilisation comme agents oestrogenes
ES2361031T3 (es) * 2004-10-18 2011-06-13 Eli Lilly And Company Benzopiranos sustituidos como agonistas selectivos del receptor beta de estrógenos.
SI1812417T1 (sl) * 2004-11-18 2009-04-30 Janssen Pharmaceutica Nv Novi derivati 2H-kromena kot selektivni modulatorji estrogenskega receptorja
EP1853578A1 (fr) * 2005-02-15 2007-11-14 Eli Lilly And Company Tetralines substituees utilisees comme antagonistes selectifs du recepteur d'oestrogenes beta
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
TW201043595A (en) 2009-03-13 2010-12-16 Organon Nv Tetrahydronaphthalen-2-ol derivatives
US8063102B2 (en) 2009-03-13 2011-11-22 N.V. Organon Tetrahydronaphthalen-2-ol derivatives
JP2016539954A (ja) 2013-12-05 2016-12-22 カロ ファーマ エービーＫａｒｏ Ｐｈａｒｍａ Ａｂ 中皮腫の処置で使用するためのエストロゲン受容体ベータアゴニスト
US11020411B2 (en) 2015-09-17 2021-06-01 Ohio State Innovation Foundation Carborane compounds and methods of use thereof
US20230114408A1 (en) * 2020-03-11 2023-04-13 Ohio State Innovation Foundation Methods of modulating t-cell activation using estrogen receptor beta (erb) agonists

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3901926A (en) * 1973-04-02 1975-08-26 Abbott Lab Alkylphenyl benzopyrans
CA2201098C (fr) 1995-09-08 2001-03-27 George G.J.M. Kuiper Recepteur orphelin
WO1999002512A1 (fr) * 1997-07-09 1999-01-21 Novo Nordisk A/S Dl-2,3-diaryl-2h-1-benzopyrans
EP1163225A1 (fr) 1999-03-17 2001-12-19 Signal Pharmaceuticals, Inc. Composes et techniques de modulation des recepteurs des oestrogenes
US6593322B1 (en) 1999-03-17 2003-07-15 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
AU4128800A (en) 1999-04-16 2000-11-02 Astrazeneca Ab Estrogen receptor-beta ligands
WO2001049673A2 (fr) 1999-12-30 2001-07-12 Signal Pharmaceuticals, Inc. Composes et procedes de modulation de recepteurs d'oestrogenes
AU2001256164A1 (en) * 2000-03-01 2001-09-12 Akzo Nobel N.V. Chroman derivatives as estrogenic compounds
AU2001254710A1 (en) 2000-03-27 2001-10-08 Akzo Nobel N.V. Non-steroidal, tetracyclic compounds for estrogen-related treatments
GB2361642A (en) 2000-10-24 2001-10-31 Karobio Ab Estrogen receptor beta (ERbeta) agonists for use in cancer treatment
UA83620C2 (ru) 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
TWI306450B (en) 2001-12-13 2009-02-21 Wyeth Corp Substituted phenyl naphthalenes as estrogenic agents
US6630508B1 (en) * 2002-02-11 2003-10-07 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor β agonists

Also Published As

Publication number Publication date
ATE362471T1 (de) 2007-06-15
WO2003044006A1 (fr) 2003-05-30
KR20040063963A (ko) 2004-07-15
JP2005513027A (ja) 2005-05-12
ECSP045113A (es) 2004-07-23
CA2467013C (fr) 2010-08-10
IL185867A (en) 2009-09-22
EA200400695A1 (ru) 2004-12-30
HU229351B1 (en) 2013-11-28
IL161325A0 (en) 2004-09-27
IL161325A (en) 2008-07-08
PL205733B1 (pl) 2010-05-31
IL185867A0 (en) 2008-01-06
DE60220179T2 (de) 2008-02-07
AU2002359283A1 (en) 2003-06-10
NO328563B1 (no) 2010-03-22
DK1448544T3 (da) 2007-10-08
NO20042583L (no) 2004-06-18
JP4381810B2 (ja) 2009-12-09
CA2467013A1 (fr) 2003-05-30
HRP20040439A2 (en) 2005-04-30
EP1448544B1 (fr) 2007-05-16
HUP0402628A2 (hu) 2005-04-28
PL374510A1 (en) 2005-10-31
AU2002359283B8 (en) 2003-06-10
PT1448544E (pt) 2007-08-10
ES2286322T3 (es) 2007-12-01
CN1312147C (zh) 2007-04-25
MXPA04004703A (es) 2004-08-19
EP1448544A1 (fr) 2004-08-25
CN1589268A (zh) 2005-03-02
US7217734B2 (en) 2007-05-15
NZ531850A (en) 2007-01-26
EA007382B1 (ru) 2006-10-27
US20040249167A1 (en) 2004-12-09
KR100950616B1 (ko) 2010-04-01
AU2002359283B2 (en) 2007-06-21
DE60220179D1 (de) 2007-06-28
CY1106726T1 (el) 2012-05-23

Similar Documents

Publication Publication Date Title
IL185867A0 (en) Substituted benzopyrans as selective estrogen receptor-beta agonists
ATE457308T1 (de) Substituierte benzopyrane als selektive antagonisten am östrogenrezeptor-beta
CY1110443T1 (el) Υποκατεστημενα βενζοπυρανια ως εκλεκτικοι αγωνιστες υποδοχεα-βητα οιστρογονων
MXPA04002070A (es) Compuestos de indazol sustituidos para el tratamiento de la inflamacion.
RS60503A (en) Substituted alkylamine derivatives and methods of use
NZ511593A (en) Substituted benzopyran analogs for the treatment of inflammation
MY141733A (en) Benzimidazole and pyridylimidazole derivatives as ligands for gabaa receptors
PL367814A1 (en) 4,5-dihydro-1h-pyrazole derivatives having potent cb1-antagonistic activity
MXPA03010134A (es) Derivados de ciclohexan-1-4-diamina sustituidos.
AU2001231710A1 (en) Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase
IL127800A (en) Highly lipophilic 7-substituted camptothecin derivatives and pharmaceutical compositions containing them
HK1080088A1 (zh) 製備c-7取代的5-雄甾烯的方法
WO2003024935A3 (fr) Composes de pyrazolyle substitues destines au traitement de l'inflammation
WO2003027075A3 (fr) Composes substitues de sulfamide benzene de pyrazolyl destines au traitement des inflammations
PL371127A1 (en) 6-aminomorphinane derivatives, method for the production and use thereof
MXPA04004606A (es) Venenos de topoisomerasa solubilizados.
EP1453812A4 (fr) Agents cytotoxiques
AU2002357184A1 (en) SUBSTITUTED 6H-DIBENZO(c,h)CHROMENES AS ESTROGENIC AGENTS
MY117975A (en) Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists
HUP0402283A3 (en) Substituted 2-pyrrolidine-2-yl-1h-indole derivatives for the treatment of migraine, process for their preparation and pharmaceutical compositions containing them
ES2103237A1 (es) Nuevo compuesto derivado del cromeno
AU2002359762A1 (en) Luminacin analogs and uses thereof
SI1453820T1 (en) Substituted 6h-dibenzo(c,h)chromenes as estrogenic agents

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20121107